Unknown

Dataset Information

0

The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

ABSTRACT: Prostate cancer remains the second leading cause of cancer-associated deaths amongst American men. Trop2, a cell surface glycoprotein, correlates with poor clinical outcome and is highly expressed in metastatic, treatment-resistant prostate cancer. High levels of Trop2 are prognostic for biochemical recurrence. Trop2 regulates tumor growth and metastatic ability of prostate cancer. Moreover, overexpression of Trop2 drives the transdifferentiation to neuroendocrine phenotype in prostate cancer. In addition, Trop2 is overexpressed across epithelial cancers and has emerged as a promising therapeutic target in various solid epithelial cancers. The FDA (Food and Drug Administration) recently approved the use of a Trop2-targeting ADC (antibody-drug conjugate), Sacituzumab Govitecan (IMMU-132), for metastatic, triple-negative breast cancer with at least two prior therapies. Here, we review the role of Trop2 in prostate tumorigenesis and its potential as a promising biomarker and therapeutic target for prostate cancer.

SUBMITTER: Shen M 

PROVIDER: S-EPMC8012837 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Shen Michelle M   Liu Shiqin S   Stoyanova Tanya T  

American journal of clinical and experimental urology 20210215 1

Prostate cancer remains the second leading cause of cancer-associated deaths amongst American men. Trop2, a cell surface glycoprotein, correlates with poor clinical outcome and is highly expressed in metastatic, treatment-resistant prostate cancer. High levels of Trop2 are prognostic for biochemical recurrence. Trop2 regulates tumor growth and metastatic ability of prostate cancer. Moreover, overexpression of Trop2 drives the transdifferentiation to neuroendocrine phenotype in prostate cancer. I  ...[more]

Similar Datasets

Unknown Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.
| S-EPMC7559260 | biostudies-literature
Unknown PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer.
| S-EPMC7565192 | biostudies-literature
Unknown Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer.
| S-EPMC8698755 | biostudies-literature
Unknown Experimental validation and pan-cancer analysis identified COL10A1 as a novel oncogene and potential therapeutic target in prostate cancer.
| S-EPMC10781495 | biostudies-literature
Unknown Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target.
| S-EPMC10537950 | biostudies-literature
Unknown MST4: A Potential Oncogene and Therapeutic Target in Breast Cancer.
| S-EPMC9777386 | biostudies-literature
Unknown Recent developments in prostate cancer biomarker research: therapeutic implications.
| S-EPMC3040536 | biostudies-other
Unknown Role of Y Box Protein-1 in cancer: As potential biomarker and novel therapeutic target.
| S-EPMC5556654 | biostudies-other
Unknown Role of ?V?3 in Prostate Cancer: Metastasis Initiator and Important Therapeutic Target.
| S-EPMC7395689 | biostudies-literature
Unknown Unveiling the role of YARS1 in bladder cancer: A prognostic biomarker and therapeutic target.
| S-EPMC10951887 | biostudies-literature